帕博利珠单抗联合醋酸阿比特龙和泼尼松治疗化疗初治转移性去势抵抗性前列腺癌:KEYNOTE-365 D队列结果
KEYNOTE-365研究D队列纳入103例化疗初治转移性去势抵抗性前列腺癌患者,接受帕博利珠单抗联合醋酸阿比特龙和泼尼松治疗。确认的前列腺特异性抗原(PSA)缓解率为56%(58/103),可测量病灶客观缓解率(ORR)为16%(6/37),中位影像学无进展生存期(rPFS)15个月,中位总生存期(OS)30个月。联合方案显示抗肿瘤活性和可接受的安全性,但3/4级丙氨酸氨基转移酶(ALT)/天冬氨酸氨基转移酶(AST)升高发生率高于单药报道。
要点
- 确认的PSA缓解率为56%(58/103例),可测量病灶ORR为16%(6/37例)。
- 中位rPFS为15个月,中位OS为30个月,24个月OS率为58%。
- 91%患者发生治疗相关不良事件,39%发生3-5级事件;1例因治疗相关肌无力综合征死亡。
核心结论
- 帕博利珠单抗联合醋酸阿比特龙和泼尼松在化疗初治mCRPC中显示抗肿瘤活性和可接受的安全性。
- 3/4级ALT/AST升高发生率高于单药报道。
研究设计与样本
- 1b/2期KEYNOTE-365研究D队列(NCT02861573),单臂设计,纳入103例化疗初治mCRPC患者。
- 患者为筛查前6个月内疾病进展,且未接受过mCRPC下一代内分泌治疗,或既往接受恩扎卢胺治疗后进展或不耐受。
- 治疗方案:帕博利珠单抗200 mg静脉注射每3周一次,醋酸阿比特龙1000 mg口服每日一次,泼尼松5 mg口服每日两次。
主要发现
- 中位随访28个月(四分位距26-31)。
- 确认的PSA缓解率为56%(58/103例)。
- RECIST v1.1可测量病灶患者的ORR为16%(6/37例)。
- 中位rPFS为15个月(95%CI 9.2-22),中位OS为30个月(95%CI 23-未达到),估计24个月OS率为58%。
- 91%患者发生治疗相关不良事件,39%发生3-5级事件;3/4级ALT升高12%,AST升高6.8%;1例因治疗相关肌无力综合征死亡。
关键数值与推荐
- 确认的PSA缓解率56%(58/103例)。
- 可测量病灶ORR 16%(6/37例)。
- 中位rPFS 15个月(95%CI 9.2-22),中位OS 30个月(95%CI 23-未达到)。
- 治疗相关不良事件发生率91%,3-5级事件39%。
- 3/4级ALT升高12%,AST升高6.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究局限性包括单臂设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Abiraterone acetate (abiraterone) plus prednisone is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Our aim was to evaluate the efficacy and safety of pembrolizumab plus abiraterone in mCRPC. METHODS: In cohort D of the phase 1b/2 KEYNOTE-365 study (NCT02861573), patients were chemotherapy-naïve, had disease progression ≤6 mo before screening, and had either not received prior next-generation hormonal agents for mCRPC or had received prior enzalutamide for mCRPC and had disease progression or became intolerant to enzalutamide. Patients received pembrolizumab 200 mg intravenously every 3 wk plus abiraterone 1000 mg orally once daily and prednisone 5 mg orally twice daily. The primary endpoints were safety, prostate-specific antigen (PSA) response rate, and objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR). Secondary endpoints included radiographic progression-free survival (rPFS) according to Prostate Cancer Clinical Trials Working Group 3-modified RECIST v1.1 by BICR and overall survival (OS). KEY FINDINGS AND LIMITATIONS: For the 103 patients who were treated, median follow-up was 28 mo (interquartile range 26-31). The confirmed PSA response rate was 56% (58/103 patients). The ORR for patients with RECIST v1.1-measurable disease was 16% (6/37 patients). Median rPFS was 15 mo (95% confidence interval 9.2-22) and median OS was 30 mo (95% confidence interval 23-not reached); the estimated 24-mo OS rate was 58%. In total, 91% of patients experienced treatment-related adverse events, and 39% experienced grade 3-5 events. Grade 3/4 elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) was observed in 12% and 6.8% of patients, respectively. One patient died due to treatment-related myasthenic syndrome. Study limitations include the single-arm design. CONCLUSIONS: Pembrolizumab plus abiraterone and prednisone demonstrated antitumor activity and acceptable safety in patients with chemotherapy-naïve mCRPC. Higher incidence of grade 3/4 elevated ALT/AST occurred than was reported for the individual agents. PATIENT SUMMARY: For patients with metastatic castratation-resistant prostate cancer, the drug combination of pembrolizumab plus abiraterone and prednisone showed antitumor activity and acceptable safety.
引用
- Yu EY, Ferrario C, Linch MD, et al. Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D. Eur Urol Oncol. 2024. PMID: 38926066. doi:10.1016/j.euo.2024.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。